SlideShare uma empresa Scribd logo
1 de 48
Baixar para ler offline
COVID-19 “Long Haulers”
January 6, 2021
CME Credit
• Bridgeport Hospital Yale New Haven Health is accredited by the Connecticut State
Medical Society to sponsor continuing medical education for physicians. The
Bridgeport Hospital Yale New Haven Health designates this live activity for a
maximum of one (1) AMA PRA Category 1 CreditsTM. Physicians should claim only
credits commensurate with the extent of their participation in the various
activities.
• This activity has been planned and implemented in accordance with the Essential
Areas and policies of the Accreditation Council for Continuing Medical Education
through the joint sponsorship of Bridgeport Hospital Yale New Haven Health and
the Weitzman Institute. Bridgeport Hospital Yale New Haven Health is accredited
by the Connecticut State Medical Society to provide continuing medical education
for physicians.
• The content of this activity is not related to products or services of an ACCME-
defined commercial interest; therefore, no one in control of content has a relevant
financial relationship to disclose and there is no potential for conflicts of interest.
COVID-19
“Long Haulers”
6 Jan 2021
www.nationaljewish.org/
21,044,020 cases on 1/5/21 with 357,156 deaths https://coronavirus.jhu.edu/map.html
COVID-19 in the United States
COVID-19 in the United States
https://coronavirus.jhu.edu/covid-19-daily-video
COVID-19 in the United States
https://coronavirus.jhu.edu/covid-19-daily-video
COVID-19 Cumulative Cases:
Curve Seen Accelerating Upwards
COVID-19 Vaccinations – Too Slow?
https://www.nytimes.com/interactive/2020/us/coronavirus-us-cases.html
News Headlines
-4.6 million in the US received a
COVID-19 vaccine, far short of ~ 20
million before the end of Dec
-Federal health officials: rollout had a slower-
than-expected start and “did not have a clear
understanding as to why”
- CDC reported 365,294 people in nursing
homes and long-term-care centers had
been given shots through a federal
program, though more than 2.5 million
doses had been distributed for those
facilities
Highly contagious COVID-19 strain
found in upstate New York, Gov.
Cuomo says
COVID-19 Live Updates: Virus Cases
in U.S. Prisons Top 500,000Source: New York Times
Resources
• Nuvance health ~1900 articles reviewed:
https://spark.adobe.com/page/sCbcTIGxitEdM/
• CDC:
https://www.cdc.gov/coronavirus/2019-ncov/index.html
https://emergency.cdc.gov/coca/calls/2020/
• WHO:
https://www.who.int/emergencies/diseases/novel-coronavirus-2019
• Johns Hopkins:
https://coronavirus.jhu.edu/map.html
• Others
https://www.thelancet.com/coronavirus
https://covidactnow.org/
COVID-19 “Long Haulers”
Emma Kaplan-Lewis, MD - Infectious Disease Attending,
Elmhurst Hospital Center, NYC Health and Hospitals
Jesse Durrance, MD - Pulmonology and Critical Care Fellow,
Elmhurst Hospital Center, NYC Health and Hospitals
Agenda
• Discuss epidemiology of post acute symptoms
related to COVID-19
• Case Presentation: Infectious Disease Perspective
• Case Presentation: Pulmonology/Critical Care
Perspective
• Key Takeaways
• Discussion/Q+A
Terminology and Epidemiology
• Post acute sequelae or ‘Long COVID’ or ‘Long Hauler’: persistent symptoms beyond 3 weeks
from initial symptom onset
• ‘Chronic COVID’: Symptoms extending beyond 12 weeks from symptom onset
• Pathophysiology: Permanent organ damage from the acute infection, ongoing inflammation
 Difficult to discern from deconditioning and sequelae from overall pandemic (lifestyle
changes, social isolation, more sedentary)
• Frequency:
 Mild disease: 35% adult patients with + COVID test in outpatient setting reported ongoing
symptoms median of 16 days after positive test
 Moderate-Severe: post hospitalization, mean 60 days since symptom onset (36 days since
hospital discharge), 87.4% reported persistent symptoms, 44.1% reported worsened QOL.
Most common symptoms: fatigue, dyspnea, joint pain, chest pain
Terminology and Epidemiology (cont.)
Most Common Reported Symptoms:
– Fatigue
– Dyspnea
– Cough
– Arthralgia
– Chest pain
– Ongoing smell/taste dysfunction
– Headache
– ‘Brain fog’ (cognitive dysfunction, memory impairment)
– Depression/anxiety, mood changes
– Other important sequelae: Metabolic disruption: new or worse diabetes,
Organizing pneumonia, Permanent kidney injury, PTSD, Myocarditis
Long Term Symptoms
Carfì A, Bernabei R, Landi F, et al. Persistent symptoms in patients after acute COVID-19. JAMA. 2020;324(6):603-605
Case #1
73 F w/ Osteogenesis Imperfecta type 3, osteoporosis, HIV (CD4 > 1000, VL UD), HTN
3/31-4/9: Hospitalized with COVID-19 pneumonia, needed 02, no intubation. Symptoms: cough, shortness
of breath, fever, loss smell and taste. Discharged on home 02 for ~ 2 weeks
4/24 post d/c follow up: Mild dyspnea, not using 02 very much, still impaired taste and smell, traumatized
by hospital experience but relieved she survived, has 2 friends who passed away from COVID-19
6/26: Reports chronic sore throat post COVID and ongoing loss of taste, decreased appetite.
Deconditioned and frail. Referred to PM&R for PT
10/7: Feels COVID symptoms have returned- cough at night, shortness of breath worse at night and
exertion, ongoing decreased smell/taste impacting appetite. CXR and TTE ordered. Recommended r/p
COVID testing. Rx Mirtazapine 7.5mg QHS
11/18: CXR clear with cardiomegaly, TTE w/ diastolic dysfunction. Reports hard to walk b/c of shortness of
breath, slowly progressive. No chest pain/pressure. Extreme fatigue on some days
11/24: Televisit - worse dyspnea, advised to go to ED, declined but will come to clinic next day
11/25: Seen in clinic, afebrile, 99% room air but desaturated 82-85% after ambulating 1-2 min. HR to 110s
while ambulating. RR 28 at rest. Lungs clear, Cardiac exam with tachycardia (regular) and faint systolic
murmur, no LE edema or JVD. Sent to ED
DDX
• PE
• Unstable angina
• CHF
• Pneumonia
• Interstitial lung disease/diffusion abnormality
• ? Other
Case #1: CXR
Case #1: TTE
• TTE - impaired left ventricular relaxation pattern with
elevated left atrial pressure, grade II diastolic
dysfunction. Small partially organized pericardial
effusion
Case #1 Continued
11/26-12/2: Hospitalized
• TTE bedside with moderate pericardial effusion, no
tamponade
• CTA with no PE, D-dimer negative, r/p COVID PCR negative
• Monitored in CCU then medical floor
• 02 sat remained stable and weaned off 02
• Discharged without 02 and recommended outpatient PFTs
Current status: Referred to cardiology and pulmonology,
continue PT for deconditioning and trying to get outpatient 02
covered
Case #2
51 F with HIV, (CD4 600, VL UD) non- IDDM, epilepsy, HTN, prior smoker (quit 10 y prior)
Admitted 1/15-1/30 for leg weakness, UTI and pneumonia. Reports ‘couldn’t walk’ and shortness of breath and fever,
required supplemental 02 no intubation. No COVID test done. CT report (no imaging because outside hospital) with
bibasilar ground glass opacities)
3/18: Non productive cough for weeks, no dyspnea, MSK pain- back and ribs, ? Pleuritic
6/24: Ongoing MSK pain- L. rib , waxing and waning cough and shortness of breath (mild)
 COVID IGG + , PCR negative
8/26: Left upper back pain worse on inspiration, cough has improved
 Sent for CTA: diffuse ground glass opacities bilateral with bibasilar alveolar airspace opacities.
9/25: Pulmonology apt for ongoing intermittent mild dyspnea and cough and abnormal CT findings, ddx: viral infection,
post COVID syndrome (ab +), plan for TTE and r/p CT chest 3 mo
 Dobutamine stress echo- negative for ischemia, normal contractility and EF
9/30: Complaints of dry cough, intermittent sore throat. No fevers
12/22: Ongoing intermittent cough, energy improved, on and off mild dyspnea
 COVID PCR negative
 Repeat CTA: Stable LLL subpleural predominant groundglass opacities with reticulation/interlobular
thickening. Interval increase in the extent of the RLL subpleural predominant groundglass opacities with
reticulation/intralobular thickening. No honeycombing. Findings nonspecific and can represent interstitial
disease/organizing pneumonia
Case #2: Initial CT (8/26/20)
Case #2: Follow-Up CT (12/22/20)
4 months later
Case #2
Current status: repeat CT with ? Organizing
pneumonia- to see pulmonology next month
(? Tx steroids). Ongoing intermittent sore throat and
dry cough, generally improving.
Case # 3
64 F with insomnia, no other medical history
PCR+ for COVID 12/1, managed outpatient, repeat PCR negative 12/19
Frequent headaches, described as if someone ‘grabbing her head and pain
behind eyes’. Not improved with Tylenol or OTC NSAIDS
Waiting for neurology referral, no prior history of chronic headache
syndrome, in meantime getting NCHCT
Post-COVID Headaches Management
• If less than 8d/m: treat as needed with OTCs
• If more than 8-10d/m, daily preventative medication needed to avoid medication
overuse:
– Cut down on OTCs if taking >10d/m as that can cause worsening of headache
frequency/severity.
– Topiramate: start 25mg QHS and increase by 25mg weekly to 100mg daily (typically 50mg
BID). Better for migraine headaches (photo/phonophobia, nausea). Can cause grogginess/may
worsen brain fog so I'd avoid if that's a major issue. Don't use if prior kidney stones, glaucoma.
– Amitriptyline: start 10-25mg QHS and can increase up to 50-75mg QHS as needed. Good
option if poor sleep/insomnia. Generally avoid if on other anti-depressants, but such a low
dose that it's generally ok to add on if needed.
– Duloxetine: start 30mg daily but good dose is 60mg daily. Helpful for paresthesias and this is
full anti-depressant dose so good if there's untreated depression but avoid if on other anti-
depressants. Also activating so take in daytime, and take with food as it can cause some
nausea.
– Valproate/Depakote: 250mg daily to BID. Can cause nausea, weight gain, tremors etc. Second
line because of side effect profile but a good headache medication so worth a try if other
options limited. Avoid in anyone with liver issues.
Post-COVID Headaches Management (cont.)
• If constant headache/"status" headache:
– Start daily preventative.
– Can also provide short course of steroids (Medrol Dose Pack) to try and break headache. Anecdotally not
much luck with steroids and Post-COVID patients but still worth a try. Avoid if contraindications to steroids.
– If steroids not an option, can also do a 3-5 day course of diclofenac 50mg BID. Since its a longer acting NSAID,
it can also break the headache cycle. Take with food, monitor for GI issues (standard NSAID concerns).
• Other things:
– Tizanidine can be helpful if taken daily, especially if there seems to be a tension component or neck pain.
Typically start lower dose at bedtime and increase as needed since its sedating.
– Other things/non medication environmental modification:
• Sleep: if poor sleep that can worsen headaches. Can treat as above with meds that help headaches and
also sleep (i.e. amitriptyline) or can try melatonin
• Water: recommend at least 2-3L daily
• Caffeine: can help with headache but can also cause headache if drinking a lot. Recommend cutting
down if excessive use.
• Preventatives can take up to 4 weeks to really start working, so don’t stop them if no
immediate improvement. Only to stop if experience side effects that are really bothersome.
If mild side effects, encourage to try continuing and see if they go away since there's
only so many medication options.
Management of Post-Acute and
Chronic COVID
• Diagnostic (depending on symptoms reported and history): PFTs, TTE, CTA,
D-dimer, troponin, pro-BNP, CRP
• CXR at 12 weeks post discharge, also for new or worsening symptoms
• A1c, close glucose monitoring for diabetics
• Ambulatory 02 saturation
• Consider pulmonology/ pulmonary rehab, cardiology referral if ongoing
severe symptoms
Management of
Chronic COVID
Greenhalgh T, Knight M, A’Court C, et al.
Management of post-acute covid-19 in primary
care. BMJ. 2020;370:m3026
Clinical Cases from the
Pulmonary/Critical Care
Perspective
Case #4
53 y.o. Hispanic male with PMH of HTN presented with 2 weeks progressive SOB
associated with cough and fever
• 3/26/20 - 9/4/20: admitted with Severe COVID-19 Pneumonia: requiring intubation
on hospital day 2 after failing NIPPV – subsequent prolonged mechanical ventilation.
• Course complicated by:
– Tension pneumothorax x 2 (different sides)
• Persistent pulmonary-pleural fistula and loculated pneumothorax
– Septic Shock with empyema
– Renal failure requiring RRT
– MDRO infection in lung
• 5/28/20 – Trach done
• Decannulation 7/27/20
• Discharged Home 9/4/2020 on 4L NC, using walker, to care of wife with
VNS/Rehab/DME arranged.
Case #4 Follow Up
• 9/10/20: Scheduled for follow up at primary care clinic – no show
• 11/18/20 : Pulmonary follow up
– Tolerating 1L NC on ambulation- no O2 at rest (keeps it on)
– Persistent tachycardia
– Mild sore throat persists
• Issues:
– Exercise tolerance vs O2 demand (real and perceived)
– Assuming personal / family life
– Nagging worry – Post-Traumatic Stress Disorder
– Cultural / Language Barriers to ongoing care
Case #4 Follow Up
• Pulmonary Function Tests:
– Moderate Restriction
– No obstruction
• 6-minute walk test
– Off O2
– 66% of predicted
– Saturation >92% on RA
– HR to >140
Case #4 Follow Up: Imaging
Case #4 Follow Up
• Psychiatry:
– 12/2/20: no show
• Neurology:
– Frequent luxation of shoulders (reportedly had this from prior)
– Sent for tests / tele-medicine visit
– 12/21/20: in-person visit for PMR regarding rehab therapy of B/L upper extremities
• Cardiology: Follow up as needed
• Pulmonary: continues to follow up in outpatient clinic
– Anti-fibrotics are under study
– Inhalers: On ICS/LABA therapy (evidence limited and indeterminate)
– PT / Rehab / O2 supplementation
– PFT Trend- under study
Post-Intensive Care Syndrome:
COVID Patients
• PICS (Post-intensive care syndrome)
• Constellation of health issues that linger after critical illness – after discharge
(wide range of incidence =/?? Detection)
• Cognitive Impairment occurs in up to 25% of patients
– Associated with delirium during hospitalization (sedation and COVID)
• Psychological Health Impairment
– PTSD, Anxiety, Depression
• Functional Impairment (>25% of patients)
– ICU Acquired neuromuscular weakness
– Prolonged mechanical ventilation / Sedation / Paralytics / MOF
• Family / Caregiver PICS - beyond just the patient
Rawal G, Yadav S, Kumar R. Post-intensive care syndrome: An overview. J Transl Intern Med. 2017;5: 90–92.
Post-Intensive Care Syndrome
Needham DM, Davidson J, Cohen H, Hopkins RO, Weinert C, Wunsch H, et al. Improving long-term outcomes after discharge from
intensive care unit: Report from a stakeholders’ conference. Crit Care Med. 2012;40: 502–509.
PICS in COVID-19 Patients
• PICS: patients have an elevated rate of re-admission
– Those with ALI/ARDS have higher rate of readmission (80%)
– Longer index admission associated with higher healthcare cost after index
admission
– Degree of inflammation associated with development of PICS
– Significant impact on home finances and ability to re-enter the workplace
• In COVID:
– Oxygen Demand: has the capacity to decrease
• 6MW test and PFTs help with objectivity
– Physical Therapy Remains extremely important
– Totality of PICS in COVID-19 patients is not yet fully appreciated
-Ruhl AP, Lord RK, Panek JA, Colantuoni E, Sepulveda KA, Chong A, et al. Health care resource use and costs of two-year survivors of acute
lung injury: An observational cohort study. Ann Am Thorac Soc. 2015;12: 392–401.
-Bangash MN, Owen A, Alderman JE, Chotalia M, Patel JM, Parekh D. COVID-19 recovery: potential treatments for post-intensive care
syndrome. Lancet Respir Med. 2020;8: 1071–1073.
Case #5
51 y.o. Male, no significant PMH, previously admitted for severe COVID-19 PNA at OSH-
Ventilated – Trach – Decannulated
• Course c/b failed extubation x 3, MRSA-VAP- Trach / PEG
• Admitted 3/18/20 for COVID-19 PNA – Trach (4/23/20) – Decannulated (5/15/20) - Discharged
(5/18/20) Home
• 6/18- admitted at OSH for acute exacerbation of “Asthma” discharged on steroids and inhalers
• 6/24- ED Visit at OSH for Dyspnea: duo-nebs – steroids, H1 blocker, inhalers- discharged
• 6/26- ED Visit at OSH for Dyspnea: duo-nebs – steroids, discharged with 5 day steroid course
• 6/28- admitted for Dyspnea, Hypoxia- stridor identified- underwent tracheal balloon dilation
(7/1)- steroid taper, discharged with improved symptoms (7/2) with follow up scheduled
Case #5: Initial Imaging
Case #5: Spirometry and Imaging
Case #5 Continued
• 7/23: Re-admitted with
progressive Dyspnea
 Noted to have voice
change
• 7/25: Repeat balloon
dilation with temporary
improvement
 Quickly relapsed with
O2 demand (5L NC
constantly)
 No obvious stridor on
exam
 PFTs post dilation
Case #5 Follow Up
• 8/3: Patient underwent tracheal
ring resection
 Trach placed during procedure
 Quickly decannulated (before
discharge)
• 8/10: Discharged home
• Follow up with Speech for
rehab therapy
 Continues to have
improvement. Mild raspy
voice, otherwise asymptomatic
 No requirement for
supplemental oxygen
Post-COVID “Long Hauler”
Take-Home Messages
• Oxygen supplementation: titration (as much physiologically as
psychologically)
– 6MW test / PFTs should be done at baseline and to monitor disease evolution
• Inhalers: individual patient decision (LABA/ICS)
• Anti-fibrotics: under investigation
• Rehab therapy: extremely important- facilitation is key
• PICS: weakness / cognition / depression / anxiety / PTSD / caretakers
• Dyspnea: keep a broad differential in mind
• Follow-up: elimination of barriers to healthcare access
Barriers to Follow-Up Care
• Disproportionate burden on racial / ethnic minority groups in hospitalization
and death rates
– Heavy Disease Burden on groups already vulnerable by traditional determinants
of health indexes
• Post-index hospitalization and Access to Care:
– Language and Cultural Barriers
• Navigation of the health system for testing / follow-up appointments
• Insurance navigation
– Economic Barriers:
• Rehabilitation
• DME – access to oxygen, prescriptions / refills
• Home care : burden of care falls on family
• Bread-winners: significant compromise in familial access to income
COVID-19 for the
“Long Haul”
Questions Regarding Each Patient:
1. What ongoing issues are they facing?
— Biological
— Psychological
— Social
2. Who is best-suited to address those issues?
3. What are the barriers the patient / family face
in meeting their needs (from HCP perspective)?
4. How can we (individual providers / system)
anticipate and help meet those demands?
References
• https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/late-sequelae accessed 12/28/20
• Carfì A, Bernabei R, Landi F, et al. Persistent symptoms in patients after acute COVID-19. JAMA.
2020;324(6):603-605.
• del Rio C, Collins LF, Malani P. Long-term health consequences of COVID-19. JAMA. 2020.
doi:10.1001/jama.2020.1971
• Fraser E. Long term respiratory complications of covid-19. BMJ. 2020;370:m3001.
doi:10.1136/bmj.m3001
• Greenhalgh T, Knight M, A’Court C, et al. Management of post-acute covid-19 in primary care. BMJ.
2020;370:m3026
• Tenforde MW, Kim SS, Lindsell CJ, et al. Symptom duration and risk factors for delayed return to
usual health among outpatients with COVID-19 in a multistate health care systems network—
United States, March-June 2020. MMWR Morb Mortal Wkly Rep. 2020;69:993-998.
• Sardari A, Tabarsi P, Borhany H, et al. Myocarditis detected after COVID-19 recovery, European
Heart Journal – Cardiovascular Imaging. 2020. https://doi.org/10.1093/ehjci/jeaa166external icon
• Lambert NJ and Survivor Corps. COVID-19 “Long Hauler” Symptoms Survey Report. Indiana
University School of Medicine; 2020. https://dig.abclocal.go.com/wls/documents/2020/072720-
wls-covid-symptom-study-doc.pdf
• Halpin, SJ, McIvor, C, Whyatt, G, et al. Postdischarge symptoms and rehabilitation needs in survivors
of COVID‐19 infection: A cross‐sectional evaluation. J Med Virol. 2020; 1– 10
• UK COVID Symptom study: https://covid.joinzoe.com/post/covid-long-
term?fbclid=IwAR1RxIcmmdL-EFjh_aI- accessed 12/28/20
Thank You!
To learn more about The Path Forward series
WeitzmanLearning.org/the-path-forward
To view previous COVID-19 sessions:
WeitzmanLearning.org/coronavirus

Mais conteúdo relacionado

Mais procurados

Management of Mild to Moderate COVID cases -VSGH Protocol
Management of Mild to Moderate COVID cases -VSGH ProtocolManagement of Mild to Moderate COVID cases -VSGH Protocol
Management of Mild to Moderate COVID cases -VSGH ProtocolNaveen Kumar
 
Remdesivir in the Management of COVID-19: Evidence Based Approach
Remdesivir in the Management of COVID-19: Evidence Based ApproachRemdesivir in the Management of COVID-19: Evidence Based Approach
Remdesivir in the Management of COVID-19: Evidence Based Approachfarah al souheil
 
Acute, Post Acute Sequelae COVID-19 Inferction PASC) and Neuro PASC
Acute, Post Acute Sequelae COVID-19 Inferction PASC) and Neuro PASCAcute, Post Acute Sequelae COVID-19 Inferction PASC) and Neuro PASC
Acute, Post Acute Sequelae COVID-19 Inferction PASC) and Neuro PASCGabriele Carbone
 
Radiological Presentation of COVID 19
Radiological Presentation of COVID 19Radiological Presentation of COVID 19
Radiological Presentation of COVID 19Gamal Agmy
 
Ebola Presentation
Ebola PresentationEbola Presentation
Ebola PresentationShanae Lee
 
COVID-19 (Coronavirus disease 2019) update
COVID-19 (Coronavirus disease 2019) updateCOVID-19 (Coronavirus disease 2019) update
COVID-19 (Coronavirus disease 2019) updateSun Yai-Cheng
 
Covid-19 Xray findings
Covid-19 Xray findingsCovid-19 Xray findings
Covid-19 Xray findingsDev Lakhera
 
High-Dose N-Acetylcysteine in Stable COPD
High-Dose N-Acetylcysteine in Stable COPDHigh-Dose N-Acetylcysteine in Stable COPD
High-Dose N-Acetylcysteine in Stable COPDDr.Aslam calicut
 
Corona Virus Disease 19 Powerpoint Presentation Slides
Corona Virus Disease 19 Powerpoint Presentation SlidesCorona Virus Disease 19 Powerpoint Presentation Slides
Corona Virus Disease 19 Powerpoint Presentation SlidesSlideTeam
 
GOLD-2023_teaching-slide-set-v1.1-2Dec2022.pptx
GOLD-2023_teaching-slide-set-v1.1-2Dec2022.pptxGOLD-2023_teaching-slide-set-v1.1-2Dec2022.pptx
GOLD-2023_teaching-slide-set-v1.1-2Dec2022.pptxssuser2433da
 
Corona Virus (SARS-Cov-2) and covid 19 disease
Corona Virus (SARS-Cov-2) and covid 19 diseaseCorona Virus (SARS-Cov-2) and covid 19 disease
Corona Virus (SARS-Cov-2) and covid 19 diseaseOKELLO ISAAC OPIO
 
COVID_19 Corona virus
COVID_19 Corona virusCOVID_19 Corona virus
COVID_19 Corona virusnosheensultan
 
SARS-CoV-2 Variant of Concern Omicron
SARS-CoV-2 Variant of Concern OmicronSARS-CoV-2 Variant of Concern Omicron
SARS-CoV-2 Variant of Concern OmicronKULDEEP VYAS
 

Mais procurados (20)

Management of Mild to Moderate COVID cases -VSGH Protocol
Management of Mild to Moderate COVID cases -VSGH ProtocolManagement of Mild to Moderate COVID cases -VSGH Protocol
Management of Mild to Moderate COVID cases -VSGH Protocol
 
Post covid -19 syndrome
Post covid -19 syndromePost covid -19 syndrome
Post covid -19 syndrome
 
Remdesivir in the Management of COVID-19: Evidence Based Approach
Remdesivir in the Management of COVID-19: Evidence Based ApproachRemdesivir in the Management of COVID-19: Evidence Based Approach
Remdesivir in the Management of COVID-19: Evidence Based Approach
 
Covid 19
Covid 19Covid 19
Covid 19
 
Acute, Post Acute Sequelae COVID-19 Inferction PASC) and Neuro PASC
Acute, Post Acute Sequelae COVID-19 Inferction PASC) and Neuro PASCAcute, Post Acute Sequelae COVID-19 Inferction PASC) and Neuro PASC
Acute, Post Acute Sequelae COVID-19 Inferction PASC) and Neuro PASC
 
Overview of COVID-19 vaccines: efficacy and priority group
Overview of COVID-19 vaccines: efficacy and priority groupOverview of COVID-19 vaccines: efficacy and priority group
Overview of COVID-19 vaccines: efficacy and priority group
 
Radiological Presentation of COVID 19
Radiological Presentation of COVID 19Radiological Presentation of COVID 19
Radiological Presentation of COVID 19
 
COVID-19 Vaccine and Vaccination
COVID-19 Vaccine and VaccinationCOVID-19 Vaccine and Vaccination
COVID-19 Vaccine and Vaccination
 
Ebola Presentation
Ebola PresentationEbola Presentation
Ebola Presentation
 
Covid 19 Vaccines
Covid 19 VaccinesCovid 19 Vaccines
Covid 19 Vaccines
 
COVID-19 (Coronavirus disease 2019) update
COVID-19 (Coronavirus disease 2019) updateCOVID-19 (Coronavirus disease 2019) update
COVID-19 (Coronavirus disease 2019) update
 
Covid-19 Xray findings
Covid-19 Xray findingsCovid-19 Xray findings
Covid-19 Xray findings
 
High-Dose N-Acetylcysteine in Stable COPD
High-Dose N-Acetylcysteine in Stable COPDHigh-Dose N-Acetylcysteine in Stable COPD
High-Dose N-Acetylcysteine in Stable COPD
 
Corona Virus Disease 19 Powerpoint Presentation Slides
Corona Virus Disease 19 Powerpoint Presentation SlidesCorona Virus Disease 19 Powerpoint Presentation Slides
Corona Virus Disease 19 Powerpoint Presentation Slides
 
GOLD-2023_teaching-slide-set-v1.1-2Dec2022.pptx
GOLD-2023_teaching-slide-set-v1.1-2Dec2022.pptxGOLD-2023_teaching-slide-set-v1.1-2Dec2022.pptx
GOLD-2023_teaching-slide-set-v1.1-2Dec2022.pptx
 
Corona Virus (SARS-Cov-2) and covid 19 disease
Corona Virus (SARS-Cov-2) and covid 19 diseaseCorona Virus (SARS-Cov-2) and covid 19 disease
Corona Virus (SARS-Cov-2) and covid 19 disease
 
COVID_19 Corona virus
COVID_19 Corona virusCOVID_19 Corona virus
COVID_19 Corona virus
 
Covid 19
Covid   19Covid   19
Covid 19
 
COVID-19
COVID-19COVID-19
COVID-19
 
SARS-CoV-2 Variant of Concern Omicron
SARS-CoV-2 Variant of Concern OmicronSARS-CoV-2 Variant of Concern Omicron
SARS-CoV-2 Variant of Concern Omicron
 

Semelhante a Weitzman ECHO COVID-19 “Long Haulers”

Case on infective endocarditis
Case on infective endocarditisCase on infective endocarditis
Case on infective endocarditisAnusha Rameshwaram
 
Management of Dengue and Malaria
Management of Dengue and MalariaManagement of Dengue and Malaria
Management of Dengue and Malariaaditigupta377
 
Covid 19 diagnosis - current updates final
Covid   19 diagnosis - current  updates finalCovid   19 diagnosis - current  updates final
Covid 19 diagnosis - current updates finalDr. Gurbilas P. Singh
 
Bilateral limb gangrene in an HIV patient due to vasculopathy: Managing the d...
Bilateral limb gangrene in an HIV patient due to vasculopathy: Managing the d...Bilateral limb gangrene in an HIV patient due to vasculopathy: Managing the d...
Bilateral limb gangrene in an HIV patient due to vasculopathy: Managing the d...Ahmad Ozair
 
Weitzman ECHO Presentations of COVID-19 in Specialty Care
Weitzman ECHO Presentations of COVID-19 in Specialty CareWeitzman ECHO Presentations of COVID-19 in Specialty Care
Weitzman ECHO Presentations of COVID-19 in Specialty CareCHC Connecticut
 
Weitzman ECHO: COVID-19 Clinical Updates & Addressing Frequently Asked Questions
Weitzman ECHO: COVID-19 Clinical Updates & Addressing Frequently Asked QuestionsWeitzman ECHO: COVID-19 Clinical Updates & Addressing Frequently Asked Questions
Weitzman ECHO: COVID-19 Clinical Updates & Addressing Frequently Asked QuestionsCHC Connecticut
 
medical presentation.pptx
medical presentation.pptxmedical presentation.pptx
medical presentation.pptxBrenda Njenga
 
Thrombophylia and COVID-19. A case report of young man 53 years old whith acu...
Thrombophylia and COVID-19. A case report of young man 53 years old whith acu...Thrombophylia and COVID-19. A case report of young man 53 years old whith acu...
Thrombophylia and COVID-19. A case report of young man 53 years old whith acu...komalicarol
 
UCMS:Final Integrated medical quiz 2018
UCMS:Final Integrated medical quiz 2018 UCMS:Final Integrated medical quiz 2018
UCMS:Final Integrated medical quiz 2018 Illuminous
 
Bloodborne Refresher 2014
Bloodborne Refresher 2014Bloodborne Refresher 2014
Bloodborne Refresher 2014Loudoun699
 
Covid 19 diagnosis and treatment
Covid 19 diagnosis and treatmentCovid 19 diagnosis and treatment
Covid 19 diagnosis and treatmentNeil Kao
 
Covid 19 diagnosis and treatment
Covid 19 diagnosis and treatmentCovid 19 diagnosis and treatment
Covid 19 diagnosis and treatmentNeil Kao
 
Dengue_Presentation3_(final).pdf
Dengue_Presentation3_(final).pdfDengue_Presentation3_(final).pdf
Dengue_Presentation3_(final).pdfShravankch
 
Facilitators workbook
Facilitators workbookFacilitators workbook
Facilitators workbookDavid Ngogoyo
 
Sepsis & Hospice Eligibility: Natural History, Prognosis & Role of Hospice
Sepsis & Hospice Eligibility: Natural History, Prognosis & Role of HospiceSepsis & Hospice Eligibility: Natural History, Prognosis & Role of Hospice
Sepsis & Hospice Eligibility: Natural History, Prognosis & Role of HospiceVITAS Healthcare
 
PHARM-D INTERNSHIP ANNUAL REPORT PRESENTATION UNDER THE GUIDENCE OF DR.R.GO...
 PHARM-D  INTERNSHIP ANNUAL REPORT PRESENTATION UNDER THE GUIDENCE OF DR.R.GO... PHARM-D  INTERNSHIP ANNUAL REPORT PRESENTATION UNDER THE GUIDENCE OF DR.R.GO...
PHARM-D INTERNSHIP ANNUAL REPORT PRESENTATION UNDER THE GUIDENCE OF DR.R.GO...DR. METI.BHARATH KUMAR
 
Covid19 corona virus
Covid19 corona virusCovid19 corona virus
Covid19 corona virusSesha Sai
 
Rapid Clostridium difficile Colitis.docx
Rapid Clostridium difficile Colitis.docxRapid Clostridium difficile Colitis.docx
Rapid Clostridium difficile Colitis.docxbkbk37
 

Semelhante a Weitzman ECHO COVID-19 “Long Haulers” (20)

Case on infective endocarditis
Case on infective endocarditisCase on infective endocarditis
Case on infective endocarditis
 
Management of Dengue and Malaria
Management of Dengue and MalariaManagement of Dengue and Malaria
Management of Dengue and Malaria
 
Covid 19 diagnosis - current updates final
Covid   19 diagnosis - current  updates finalCovid   19 diagnosis - current  updates final
Covid 19 diagnosis - current updates final
 
Early recognition of meningitis
Early recognition of meningitisEarly recognition of meningitis
Early recognition of meningitis
 
Covid 19 and CHD
Covid 19 and CHDCovid 19 and CHD
Covid 19 and CHD
 
Bilateral limb gangrene in an HIV patient due to vasculopathy: Managing the d...
Bilateral limb gangrene in an HIV patient due to vasculopathy: Managing the d...Bilateral limb gangrene in an HIV patient due to vasculopathy: Managing the d...
Bilateral limb gangrene in an HIV patient due to vasculopathy: Managing the d...
 
Weitzman ECHO Presentations of COVID-19 in Specialty Care
Weitzman ECHO Presentations of COVID-19 in Specialty CareWeitzman ECHO Presentations of COVID-19 in Specialty Care
Weitzman ECHO Presentations of COVID-19 in Specialty Care
 
Weitzman ECHO: COVID-19 Clinical Updates & Addressing Frequently Asked Questions
Weitzman ECHO: COVID-19 Clinical Updates & Addressing Frequently Asked QuestionsWeitzman ECHO: COVID-19 Clinical Updates & Addressing Frequently Asked Questions
Weitzman ECHO: COVID-19 Clinical Updates & Addressing Frequently Asked Questions
 
medical presentation.pptx
medical presentation.pptxmedical presentation.pptx
medical presentation.pptx
 
Thrombophylia and COVID-19. A case report of young man 53 years old whith acu...
Thrombophylia and COVID-19. A case report of young man 53 years old whith acu...Thrombophylia and COVID-19. A case report of young man 53 years old whith acu...
Thrombophylia and COVID-19. A case report of young man 53 years old whith acu...
 
UCMS:Final Integrated medical quiz 2018
UCMS:Final Integrated medical quiz 2018 UCMS:Final Integrated medical quiz 2018
UCMS:Final Integrated medical quiz 2018
 
Bloodborne Refresher 2014
Bloodborne Refresher 2014Bloodborne Refresher 2014
Bloodborne Refresher 2014
 
Covid 19 diagnosis and treatment
Covid 19 diagnosis and treatmentCovid 19 diagnosis and treatment
Covid 19 diagnosis and treatment
 
Covid 19 diagnosis and treatment
Covid 19 diagnosis and treatmentCovid 19 diagnosis and treatment
Covid 19 diagnosis and treatment
 
Dengue_Presentation3_(final).pdf
Dengue_Presentation3_(final).pdfDengue_Presentation3_(final).pdf
Dengue_Presentation3_(final).pdf
 
Facilitators workbook
Facilitators workbookFacilitators workbook
Facilitators workbook
 
Sepsis & Hospice Eligibility: Natural History, Prognosis & Role of Hospice
Sepsis & Hospice Eligibility: Natural History, Prognosis & Role of HospiceSepsis & Hospice Eligibility: Natural History, Prognosis & Role of Hospice
Sepsis & Hospice Eligibility: Natural History, Prognosis & Role of Hospice
 
PHARM-D INTERNSHIP ANNUAL REPORT PRESENTATION UNDER THE GUIDENCE OF DR.R.GO...
 PHARM-D  INTERNSHIP ANNUAL REPORT PRESENTATION UNDER THE GUIDENCE OF DR.R.GO... PHARM-D  INTERNSHIP ANNUAL REPORT PRESENTATION UNDER THE GUIDENCE OF DR.R.GO...
PHARM-D INTERNSHIP ANNUAL REPORT PRESENTATION UNDER THE GUIDENCE OF DR.R.GO...
 
Covid19 corona virus
Covid19 corona virusCovid19 corona virus
Covid19 corona virus
 
Rapid Clostridium difficile Colitis.docx
Rapid Clostridium difficile Colitis.docxRapid Clostridium difficile Colitis.docx
Rapid Clostridium difficile Colitis.docx
 

Mais de CHC Connecticut

Re-engaging Patients in Dental Care
Re-engaging Patients in Dental CareRe-engaging Patients in Dental Care
Re-engaging Patients in Dental CareCHC Connecticut
 
NTTAP Webinar Series - June 7, 2023: Integrating HIV Care into Training and E...
NTTAP Webinar Series - June 7, 2023: Integrating HIV Care into Training and E...NTTAP Webinar Series - June 7, 2023: Integrating HIV Care into Training and E...
NTTAP Webinar Series - June 7, 2023: Integrating HIV Care into Training and E...CHC Connecticut
 
Utilizing the Readiness to Train Assessment Tool (RTAT™) To Assess Your Capac...
Utilizing the Readiness to Train Assessment Tool (RTAT™) To Assess Your Capac...Utilizing the Readiness to Train Assessment Tool (RTAT™) To Assess Your Capac...
Utilizing the Readiness to Train Assessment Tool (RTAT™) To Assess Your Capac...CHC Connecticut
 
NTTAP Webinar Series - May 18, 2023: The Changing Landscape of Behavioral Hea...
NTTAP Webinar Series - May 18, 2023: The Changing Landscape of Behavioral Hea...NTTAP Webinar Series - May 18, 2023: The Changing Landscape of Behavioral Hea...
NTTAP Webinar Series - May 18, 2023: The Changing Landscape of Behavioral Hea...CHC Connecticut
 
Newborn Screening - May 9, 2023
Newborn Screening - May 9, 2023Newborn Screening - May 9, 2023
Newborn Screening - May 9, 2023CHC Connecticut
 
Health Professions Student Training Webinar: Assessing Organizational Capacity
Health Professions Student Training Webinar: Assessing Organizational CapacityHealth Professions Student Training Webinar: Assessing Organizational Capacity
Health Professions Student Training Webinar: Assessing Organizational CapacityCHC Connecticut
 
Training the Next Generation: Investing in Workforce Training
Training the Next Generation: Investing in Workforce TrainingTraining the Next Generation: Investing in Workforce Training
Training the Next Generation: Investing in Workforce TrainingCHC Connecticut
 
NTTAP Webinar Series - April 13, 2023: Quality Improvement Strategies in a Te...
NTTAP Webinar Series - April 13, 2023: Quality Improvement Strategies in a Te...NTTAP Webinar Series - April 13, 2023: Quality Improvement Strategies in a Te...
NTTAP Webinar Series - April 13, 2023: Quality Improvement Strategies in a Te...CHC Connecticut
 
Addressing Genetics Workforce Shortage - April 11, 2023
Addressing Genetics Workforce Shortage - April 11, 2023Addressing Genetics Workforce Shortage - April 11, 2023
Addressing Genetics Workforce Shortage - April 11, 2023CHC Connecticut
 
Implementation of Timely and Effective Transitional Care Management Processes
Implementation of Timely and Effective Transitional Care Management ProcessesImplementation of Timely and Effective Transitional Care Management Processes
Implementation of Timely and Effective Transitional Care Management ProcessesCHC Connecticut
 
Direct to Consumer Test and Ancestry Testing - March 14, 2023
Direct to Consumer Test and Ancestry Testing - March 14, 2023Direct to Consumer Test and Ancestry Testing - March 14, 2023
Direct to Consumer Test and Ancestry Testing - March 14, 2023CHC Connecticut
 
Implement Behavioral Health Training Programs to Address a Crucial National S...
Implement Behavioral Health Training Programs to Address a Crucial National S...Implement Behavioral Health Training Programs to Address a Crucial National S...
Implement Behavioral Health Training Programs to Address a Crucial National S...CHC Connecticut
 
Genetic Connections to Breast Cancer - February 14, 2023
Genetic Connections to Breast Cancer - February 14, 2023Genetic Connections to Breast Cancer - February 14, 2023
Genetic Connections to Breast Cancer - February 14, 2023CHC Connecticut
 
Connective Tissue Disorders Slides - January 17, 2023
Connective Tissue Disorders Slides - January 17, 2023Connective Tissue Disorders Slides - January 17, 2023
Connective Tissue Disorders Slides - January 17, 2023CHC Connecticut
 
Implementation of Facial Recognition Software for Clinical Genetics Practice...
 Implementation of Facial Recognition Software for Clinical Genetics Practice... Implementation of Facial Recognition Software for Clinical Genetics Practice...
Implementation of Facial Recognition Software for Clinical Genetics Practice...CHC Connecticut
 
HIV Prevention: Combating PrEP Implementation Challenges
HIV Prevention: Combating PrEP Implementation ChallengesHIV Prevention: Combating PrEP Implementation Challenges
HIV Prevention: Combating PrEP Implementation ChallengesCHC Connecticut
 
NTTAP Webinar Series - December 7, 2022: Advancing Team-Based Care: Enhancing...
NTTAP Webinar Series - December 7, 2022: Advancing Team-Based Care: Enhancing...NTTAP Webinar Series - December 7, 2022: Advancing Team-Based Care: Enhancing...
NTTAP Webinar Series - December 7, 2022: Advancing Team-Based Care: Enhancing...CHC Connecticut
 
Genetics Cases and Resources Webinar Slides - November 8, 2022
Genetics Cases and Resources Webinar Slides - November 8, 2022Genetics Cases and Resources Webinar Slides - November 8, 2022
Genetics Cases and Resources Webinar Slides - November 8, 2022CHC Connecticut
 
NTTAP Webinar: Postgraduate NP/PA Residency: Discussing your Key Program Staf...
NTTAP Webinar: Postgraduate NP/PA Residency: Discussing your Key Program Staf...NTTAP Webinar: Postgraduate NP/PA Residency: Discussing your Key Program Staf...
NTTAP Webinar: Postgraduate NP/PA Residency: Discussing your Key Program Staf...CHC Connecticut
 
Training the Next Generation within Primary Care
Training the Next Generation within Primary CareTraining the Next Generation within Primary Care
Training the Next Generation within Primary CareCHC Connecticut
 

Mais de CHC Connecticut (20)

Re-engaging Patients in Dental Care
Re-engaging Patients in Dental CareRe-engaging Patients in Dental Care
Re-engaging Patients in Dental Care
 
NTTAP Webinar Series - June 7, 2023: Integrating HIV Care into Training and E...
NTTAP Webinar Series - June 7, 2023: Integrating HIV Care into Training and E...NTTAP Webinar Series - June 7, 2023: Integrating HIV Care into Training and E...
NTTAP Webinar Series - June 7, 2023: Integrating HIV Care into Training and E...
 
Utilizing the Readiness to Train Assessment Tool (RTAT™) To Assess Your Capac...
Utilizing the Readiness to Train Assessment Tool (RTAT™) To Assess Your Capac...Utilizing the Readiness to Train Assessment Tool (RTAT™) To Assess Your Capac...
Utilizing the Readiness to Train Assessment Tool (RTAT™) To Assess Your Capac...
 
NTTAP Webinar Series - May 18, 2023: The Changing Landscape of Behavioral Hea...
NTTAP Webinar Series - May 18, 2023: The Changing Landscape of Behavioral Hea...NTTAP Webinar Series - May 18, 2023: The Changing Landscape of Behavioral Hea...
NTTAP Webinar Series - May 18, 2023: The Changing Landscape of Behavioral Hea...
 
Newborn Screening - May 9, 2023
Newborn Screening - May 9, 2023Newborn Screening - May 9, 2023
Newborn Screening - May 9, 2023
 
Health Professions Student Training Webinar: Assessing Organizational Capacity
Health Professions Student Training Webinar: Assessing Organizational CapacityHealth Professions Student Training Webinar: Assessing Organizational Capacity
Health Professions Student Training Webinar: Assessing Organizational Capacity
 
Training the Next Generation: Investing in Workforce Training
Training the Next Generation: Investing in Workforce TrainingTraining the Next Generation: Investing in Workforce Training
Training the Next Generation: Investing in Workforce Training
 
NTTAP Webinar Series - April 13, 2023: Quality Improvement Strategies in a Te...
NTTAP Webinar Series - April 13, 2023: Quality Improvement Strategies in a Te...NTTAP Webinar Series - April 13, 2023: Quality Improvement Strategies in a Te...
NTTAP Webinar Series - April 13, 2023: Quality Improvement Strategies in a Te...
 
Addressing Genetics Workforce Shortage - April 11, 2023
Addressing Genetics Workforce Shortage - April 11, 2023Addressing Genetics Workforce Shortage - April 11, 2023
Addressing Genetics Workforce Shortage - April 11, 2023
 
Implementation of Timely and Effective Transitional Care Management Processes
Implementation of Timely and Effective Transitional Care Management ProcessesImplementation of Timely and Effective Transitional Care Management Processes
Implementation of Timely and Effective Transitional Care Management Processes
 
Direct to Consumer Test and Ancestry Testing - March 14, 2023
Direct to Consumer Test and Ancestry Testing - March 14, 2023Direct to Consumer Test and Ancestry Testing - March 14, 2023
Direct to Consumer Test and Ancestry Testing - March 14, 2023
 
Implement Behavioral Health Training Programs to Address a Crucial National S...
Implement Behavioral Health Training Programs to Address a Crucial National S...Implement Behavioral Health Training Programs to Address a Crucial National S...
Implement Behavioral Health Training Programs to Address a Crucial National S...
 
Genetic Connections to Breast Cancer - February 14, 2023
Genetic Connections to Breast Cancer - February 14, 2023Genetic Connections to Breast Cancer - February 14, 2023
Genetic Connections to Breast Cancer - February 14, 2023
 
Connective Tissue Disorders Slides - January 17, 2023
Connective Tissue Disorders Slides - January 17, 2023Connective Tissue Disorders Slides - January 17, 2023
Connective Tissue Disorders Slides - January 17, 2023
 
Implementation of Facial Recognition Software for Clinical Genetics Practice...
 Implementation of Facial Recognition Software for Clinical Genetics Practice... Implementation of Facial Recognition Software for Clinical Genetics Practice...
Implementation of Facial Recognition Software for Clinical Genetics Practice...
 
HIV Prevention: Combating PrEP Implementation Challenges
HIV Prevention: Combating PrEP Implementation ChallengesHIV Prevention: Combating PrEP Implementation Challenges
HIV Prevention: Combating PrEP Implementation Challenges
 
NTTAP Webinar Series - December 7, 2022: Advancing Team-Based Care: Enhancing...
NTTAP Webinar Series - December 7, 2022: Advancing Team-Based Care: Enhancing...NTTAP Webinar Series - December 7, 2022: Advancing Team-Based Care: Enhancing...
NTTAP Webinar Series - December 7, 2022: Advancing Team-Based Care: Enhancing...
 
Genetics Cases and Resources Webinar Slides - November 8, 2022
Genetics Cases and Resources Webinar Slides - November 8, 2022Genetics Cases and Resources Webinar Slides - November 8, 2022
Genetics Cases and Resources Webinar Slides - November 8, 2022
 
NTTAP Webinar: Postgraduate NP/PA Residency: Discussing your Key Program Staf...
NTTAP Webinar: Postgraduate NP/PA Residency: Discussing your Key Program Staf...NTTAP Webinar: Postgraduate NP/PA Residency: Discussing your Key Program Staf...
NTTAP Webinar: Postgraduate NP/PA Residency: Discussing your Key Program Staf...
 
Training the Next Generation within Primary Care
Training the Next Generation within Primary CareTraining the Next Generation within Primary Care
Training the Next Generation within Primary Care
 

Último

"Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio..."Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio...Sujoy Dasgupta
 
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...Shubhanshu Gaurav
 
ayurvedic formulations herbal drug technologyppt
ayurvedic formulations herbal drug technologypptayurvedic formulations herbal drug technologyppt
ayurvedic formulations herbal drug technologypptPradnya Wadekar
 
AUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functionsAUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functionsMedicoseAcademics
 
Using Data Visualization in Public Health Communications
Using Data Visualization in Public Health CommunicationsUsing Data Visualization in Public Health Communications
Using Data Visualization in Public Health Communicationskatiequigley33
 
High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)kishan singh tomar
 
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA .pdf
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA    .pdfSGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA    .pdf
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA .pdfHongBiThi1
 
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdfSGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdfHongBiThi1
 
Role of Soap based and synthetic or syndets bar
Role of  Soap based and synthetic or syndets barRole of  Soap based and synthetic or syndets bar
Role of Soap based and synthetic or syndets barmohitRahangdale
 
AORTIC DISSECTION and management of aortic dissection
AORTIC DISSECTION and management of aortic dissectionAORTIC DISSECTION and management of aortic dissection
AORTIC DISSECTION and management of aortic dissectiondrhanifmohdali
 
pA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacologypA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacologyDeepakDaniel9
 
blood bank management system project report
blood bank management system project reportblood bank management system project report
blood bank management system project reportNARMADAPETROLEUMGAS
 
Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.Vaikunthan Rajaratnam
 
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdfPAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdfDolisha Warbi
 
Pharmacokinetic Models by Dr. Ram D. Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D.  Bawankar.pptPharmacokinetic Models by Dr. Ram D.  Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D. Bawankar.pptRamDBawankar1
 
Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024EwoutSteyerberg1
 
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdfCONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdfDolisha Warbi
 

Último (20)

GOUT UPDATE AHMED YEHIA 2024, case based approach with application of the lat...
GOUT UPDATE AHMED YEHIA 2024, case based approach with application of the lat...GOUT UPDATE AHMED YEHIA 2024, case based approach with application of the lat...
GOUT UPDATE AHMED YEHIA 2024, case based approach with application of the lat...
 
"Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio..."Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio...
 
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
 
Rheumatoid arthritis Part 1, case based approach with application of the late...
Rheumatoid arthritis Part 1, case based approach with application of the late...Rheumatoid arthritis Part 1, case based approach with application of the late...
Rheumatoid arthritis Part 1, case based approach with application of the late...
 
ayurvedic formulations herbal drug technologyppt
ayurvedic formulations herbal drug technologypptayurvedic formulations herbal drug technologyppt
ayurvedic formulations herbal drug technologyppt
 
AUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functionsAUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functions
 
Using Data Visualization in Public Health Communications
Using Data Visualization in Public Health CommunicationsUsing Data Visualization in Public Health Communications
Using Data Visualization in Public Health Communications
 
High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)
 
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA .pdf
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA    .pdfSGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA    .pdf
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA .pdf
 
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdfSGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
 
American College of physicians ACP high value care recommendations in rheumat...
American College of physicians ACP high value care recommendations in rheumat...American College of physicians ACP high value care recommendations in rheumat...
American College of physicians ACP high value care recommendations in rheumat...
 
Role of Soap based and synthetic or syndets bar
Role of  Soap based and synthetic or syndets barRole of  Soap based and synthetic or syndets bar
Role of Soap based and synthetic or syndets bar
 
AORTIC DISSECTION and management of aortic dissection
AORTIC DISSECTION and management of aortic dissectionAORTIC DISSECTION and management of aortic dissection
AORTIC DISSECTION and management of aortic dissection
 
pA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacologypA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacology
 
blood bank management system project report
blood bank management system project reportblood bank management system project report
blood bank management system project report
 
Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.
 
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdfPAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
 
Pharmacokinetic Models by Dr. Ram D. Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D.  Bawankar.pptPharmacokinetic Models by Dr. Ram D.  Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D. Bawankar.ppt
 
Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024
 
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdfCONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
 

Weitzman ECHO COVID-19 “Long Haulers”

  • 2. CME Credit • Bridgeport Hospital Yale New Haven Health is accredited by the Connecticut State Medical Society to sponsor continuing medical education for physicians. The Bridgeport Hospital Yale New Haven Health designates this live activity for a maximum of one (1) AMA PRA Category 1 CreditsTM. Physicians should claim only credits commensurate with the extent of their participation in the various activities. • This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of Bridgeport Hospital Yale New Haven Health and the Weitzman Institute. Bridgeport Hospital Yale New Haven Health is accredited by the Connecticut State Medical Society to provide continuing medical education for physicians. • The content of this activity is not related to products or services of an ACCME- defined commercial interest; therefore, no one in control of content has a relevant financial relationship to disclose and there is no potential for conflicts of interest.
  • 3. COVID-19 “Long Haulers” 6 Jan 2021 www.nationaljewish.org/
  • 4. 21,044,020 cases on 1/5/21 with 357,156 deaths https://coronavirus.jhu.edu/map.html COVID-19 in the United States
  • 5. COVID-19 in the United States https://coronavirus.jhu.edu/covid-19-daily-video
  • 6. COVID-19 in the United States https://coronavirus.jhu.edu/covid-19-daily-video
  • 7. COVID-19 Cumulative Cases: Curve Seen Accelerating Upwards
  • 8. COVID-19 Vaccinations – Too Slow? https://www.nytimes.com/interactive/2020/us/coronavirus-us-cases.html
  • 9. News Headlines -4.6 million in the US received a COVID-19 vaccine, far short of ~ 20 million before the end of Dec -Federal health officials: rollout had a slower- than-expected start and “did not have a clear understanding as to why” - CDC reported 365,294 people in nursing homes and long-term-care centers had been given shots through a federal program, though more than 2.5 million doses had been distributed for those facilities Highly contagious COVID-19 strain found in upstate New York, Gov. Cuomo says COVID-19 Live Updates: Virus Cases in U.S. Prisons Top 500,000Source: New York Times
  • 10. Resources • Nuvance health ~1900 articles reviewed: https://spark.adobe.com/page/sCbcTIGxitEdM/ • CDC: https://www.cdc.gov/coronavirus/2019-ncov/index.html https://emergency.cdc.gov/coca/calls/2020/ • WHO: https://www.who.int/emergencies/diseases/novel-coronavirus-2019 • Johns Hopkins: https://coronavirus.jhu.edu/map.html • Others https://www.thelancet.com/coronavirus https://covidactnow.org/
  • 11. COVID-19 “Long Haulers” Emma Kaplan-Lewis, MD - Infectious Disease Attending, Elmhurst Hospital Center, NYC Health and Hospitals Jesse Durrance, MD - Pulmonology and Critical Care Fellow, Elmhurst Hospital Center, NYC Health and Hospitals
  • 12. Agenda • Discuss epidemiology of post acute symptoms related to COVID-19 • Case Presentation: Infectious Disease Perspective • Case Presentation: Pulmonology/Critical Care Perspective • Key Takeaways • Discussion/Q+A
  • 13. Terminology and Epidemiology • Post acute sequelae or ‘Long COVID’ or ‘Long Hauler’: persistent symptoms beyond 3 weeks from initial symptom onset • ‘Chronic COVID’: Symptoms extending beyond 12 weeks from symptom onset • Pathophysiology: Permanent organ damage from the acute infection, ongoing inflammation  Difficult to discern from deconditioning and sequelae from overall pandemic (lifestyle changes, social isolation, more sedentary) • Frequency:  Mild disease: 35% adult patients with + COVID test in outpatient setting reported ongoing symptoms median of 16 days after positive test  Moderate-Severe: post hospitalization, mean 60 days since symptom onset (36 days since hospital discharge), 87.4% reported persistent symptoms, 44.1% reported worsened QOL. Most common symptoms: fatigue, dyspnea, joint pain, chest pain
  • 14. Terminology and Epidemiology (cont.) Most Common Reported Symptoms: – Fatigue – Dyspnea – Cough – Arthralgia – Chest pain – Ongoing smell/taste dysfunction – Headache – ‘Brain fog’ (cognitive dysfunction, memory impairment) – Depression/anxiety, mood changes – Other important sequelae: Metabolic disruption: new or worse diabetes, Organizing pneumonia, Permanent kidney injury, PTSD, Myocarditis
  • 15. Long Term Symptoms Carfì A, Bernabei R, Landi F, et al. Persistent symptoms in patients after acute COVID-19. JAMA. 2020;324(6):603-605
  • 16. Case #1 73 F w/ Osteogenesis Imperfecta type 3, osteoporosis, HIV (CD4 > 1000, VL UD), HTN 3/31-4/9: Hospitalized with COVID-19 pneumonia, needed 02, no intubation. Symptoms: cough, shortness of breath, fever, loss smell and taste. Discharged on home 02 for ~ 2 weeks 4/24 post d/c follow up: Mild dyspnea, not using 02 very much, still impaired taste and smell, traumatized by hospital experience but relieved she survived, has 2 friends who passed away from COVID-19 6/26: Reports chronic sore throat post COVID and ongoing loss of taste, decreased appetite. Deconditioned and frail. Referred to PM&R for PT 10/7: Feels COVID symptoms have returned- cough at night, shortness of breath worse at night and exertion, ongoing decreased smell/taste impacting appetite. CXR and TTE ordered. Recommended r/p COVID testing. Rx Mirtazapine 7.5mg QHS 11/18: CXR clear with cardiomegaly, TTE w/ diastolic dysfunction. Reports hard to walk b/c of shortness of breath, slowly progressive. No chest pain/pressure. Extreme fatigue on some days 11/24: Televisit - worse dyspnea, advised to go to ED, declined but will come to clinic next day 11/25: Seen in clinic, afebrile, 99% room air but desaturated 82-85% after ambulating 1-2 min. HR to 110s while ambulating. RR 28 at rest. Lungs clear, Cardiac exam with tachycardia (regular) and faint systolic murmur, no LE edema or JVD. Sent to ED
  • 17. DDX • PE • Unstable angina • CHF • Pneumonia • Interstitial lung disease/diffusion abnormality • ? Other
  • 19. Case #1: TTE • TTE - impaired left ventricular relaxation pattern with elevated left atrial pressure, grade II diastolic dysfunction. Small partially organized pericardial effusion
  • 20. Case #1 Continued 11/26-12/2: Hospitalized • TTE bedside with moderate pericardial effusion, no tamponade • CTA with no PE, D-dimer negative, r/p COVID PCR negative • Monitored in CCU then medical floor • 02 sat remained stable and weaned off 02 • Discharged without 02 and recommended outpatient PFTs Current status: Referred to cardiology and pulmonology, continue PT for deconditioning and trying to get outpatient 02 covered
  • 21. Case #2 51 F with HIV, (CD4 600, VL UD) non- IDDM, epilepsy, HTN, prior smoker (quit 10 y prior) Admitted 1/15-1/30 for leg weakness, UTI and pneumonia. Reports ‘couldn’t walk’ and shortness of breath and fever, required supplemental 02 no intubation. No COVID test done. CT report (no imaging because outside hospital) with bibasilar ground glass opacities) 3/18: Non productive cough for weeks, no dyspnea, MSK pain- back and ribs, ? Pleuritic 6/24: Ongoing MSK pain- L. rib , waxing and waning cough and shortness of breath (mild)  COVID IGG + , PCR negative 8/26: Left upper back pain worse on inspiration, cough has improved  Sent for CTA: diffuse ground glass opacities bilateral with bibasilar alveolar airspace opacities. 9/25: Pulmonology apt for ongoing intermittent mild dyspnea and cough and abnormal CT findings, ddx: viral infection, post COVID syndrome (ab +), plan for TTE and r/p CT chest 3 mo  Dobutamine stress echo- negative for ischemia, normal contractility and EF 9/30: Complaints of dry cough, intermittent sore throat. No fevers 12/22: Ongoing intermittent cough, energy improved, on and off mild dyspnea  COVID PCR negative  Repeat CTA: Stable LLL subpleural predominant groundglass opacities with reticulation/interlobular thickening. Interval increase in the extent of the RLL subpleural predominant groundglass opacities with reticulation/intralobular thickening. No honeycombing. Findings nonspecific and can represent interstitial disease/organizing pneumonia
  • 22. Case #2: Initial CT (8/26/20)
  • 23. Case #2: Follow-Up CT (12/22/20) 4 months later
  • 24. Case #2 Current status: repeat CT with ? Organizing pneumonia- to see pulmonology next month (? Tx steroids). Ongoing intermittent sore throat and dry cough, generally improving.
  • 25. Case # 3 64 F with insomnia, no other medical history PCR+ for COVID 12/1, managed outpatient, repeat PCR negative 12/19 Frequent headaches, described as if someone ‘grabbing her head and pain behind eyes’. Not improved with Tylenol or OTC NSAIDS Waiting for neurology referral, no prior history of chronic headache syndrome, in meantime getting NCHCT
  • 26. Post-COVID Headaches Management • If less than 8d/m: treat as needed with OTCs • If more than 8-10d/m, daily preventative medication needed to avoid medication overuse: – Cut down on OTCs if taking >10d/m as that can cause worsening of headache frequency/severity. – Topiramate: start 25mg QHS and increase by 25mg weekly to 100mg daily (typically 50mg BID). Better for migraine headaches (photo/phonophobia, nausea). Can cause grogginess/may worsen brain fog so I'd avoid if that's a major issue. Don't use if prior kidney stones, glaucoma. – Amitriptyline: start 10-25mg QHS and can increase up to 50-75mg QHS as needed. Good option if poor sleep/insomnia. Generally avoid if on other anti-depressants, but such a low dose that it's generally ok to add on if needed. – Duloxetine: start 30mg daily but good dose is 60mg daily. Helpful for paresthesias and this is full anti-depressant dose so good if there's untreated depression but avoid if on other anti- depressants. Also activating so take in daytime, and take with food as it can cause some nausea. – Valproate/Depakote: 250mg daily to BID. Can cause nausea, weight gain, tremors etc. Second line because of side effect profile but a good headache medication so worth a try if other options limited. Avoid in anyone with liver issues.
  • 27. Post-COVID Headaches Management (cont.) • If constant headache/"status" headache: – Start daily preventative. – Can also provide short course of steroids (Medrol Dose Pack) to try and break headache. Anecdotally not much luck with steroids and Post-COVID patients but still worth a try. Avoid if contraindications to steroids. – If steroids not an option, can also do a 3-5 day course of diclofenac 50mg BID. Since its a longer acting NSAID, it can also break the headache cycle. Take with food, monitor for GI issues (standard NSAID concerns). • Other things: – Tizanidine can be helpful if taken daily, especially if there seems to be a tension component or neck pain. Typically start lower dose at bedtime and increase as needed since its sedating. – Other things/non medication environmental modification: • Sleep: if poor sleep that can worsen headaches. Can treat as above with meds that help headaches and also sleep (i.e. amitriptyline) or can try melatonin • Water: recommend at least 2-3L daily • Caffeine: can help with headache but can also cause headache if drinking a lot. Recommend cutting down if excessive use. • Preventatives can take up to 4 weeks to really start working, so don’t stop them if no immediate improvement. Only to stop if experience side effects that are really bothersome. If mild side effects, encourage to try continuing and see if they go away since there's only so many medication options.
  • 28. Management of Post-Acute and Chronic COVID • Diagnostic (depending on symptoms reported and history): PFTs, TTE, CTA, D-dimer, troponin, pro-BNP, CRP • CXR at 12 weeks post discharge, also for new or worsening symptoms • A1c, close glucose monitoring for diabetics • Ambulatory 02 saturation • Consider pulmonology/ pulmonary rehab, cardiology referral if ongoing severe symptoms
  • 29. Management of Chronic COVID Greenhalgh T, Knight M, A’Court C, et al. Management of post-acute covid-19 in primary care. BMJ. 2020;370:m3026
  • 30. Clinical Cases from the Pulmonary/Critical Care Perspective
  • 31. Case #4 53 y.o. Hispanic male with PMH of HTN presented with 2 weeks progressive SOB associated with cough and fever • 3/26/20 - 9/4/20: admitted with Severe COVID-19 Pneumonia: requiring intubation on hospital day 2 after failing NIPPV – subsequent prolonged mechanical ventilation. • Course complicated by: – Tension pneumothorax x 2 (different sides) • Persistent pulmonary-pleural fistula and loculated pneumothorax – Septic Shock with empyema – Renal failure requiring RRT – MDRO infection in lung • 5/28/20 – Trach done • Decannulation 7/27/20 • Discharged Home 9/4/2020 on 4L NC, using walker, to care of wife with VNS/Rehab/DME arranged.
  • 32. Case #4 Follow Up • 9/10/20: Scheduled for follow up at primary care clinic – no show • 11/18/20 : Pulmonary follow up – Tolerating 1L NC on ambulation- no O2 at rest (keeps it on) – Persistent tachycardia – Mild sore throat persists • Issues: – Exercise tolerance vs O2 demand (real and perceived) – Assuming personal / family life – Nagging worry – Post-Traumatic Stress Disorder – Cultural / Language Barriers to ongoing care
  • 33. Case #4 Follow Up • Pulmonary Function Tests: – Moderate Restriction – No obstruction • 6-minute walk test – Off O2 – 66% of predicted – Saturation >92% on RA – HR to >140
  • 34. Case #4 Follow Up: Imaging
  • 35. Case #4 Follow Up • Psychiatry: – 12/2/20: no show • Neurology: – Frequent luxation of shoulders (reportedly had this from prior) – Sent for tests / tele-medicine visit – 12/21/20: in-person visit for PMR regarding rehab therapy of B/L upper extremities • Cardiology: Follow up as needed • Pulmonary: continues to follow up in outpatient clinic – Anti-fibrotics are under study – Inhalers: On ICS/LABA therapy (evidence limited and indeterminate) – PT / Rehab / O2 supplementation – PFT Trend- under study
  • 36. Post-Intensive Care Syndrome: COVID Patients • PICS (Post-intensive care syndrome) • Constellation of health issues that linger after critical illness – after discharge (wide range of incidence =/?? Detection) • Cognitive Impairment occurs in up to 25% of patients – Associated with delirium during hospitalization (sedation and COVID) • Psychological Health Impairment – PTSD, Anxiety, Depression • Functional Impairment (>25% of patients) – ICU Acquired neuromuscular weakness – Prolonged mechanical ventilation / Sedation / Paralytics / MOF • Family / Caregiver PICS - beyond just the patient Rawal G, Yadav S, Kumar R. Post-intensive care syndrome: An overview. J Transl Intern Med. 2017;5: 90–92.
  • 37. Post-Intensive Care Syndrome Needham DM, Davidson J, Cohen H, Hopkins RO, Weinert C, Wunsch H, et al. Improving long-term outcomes after discharge from intensive care unit: Report from a stakeholders’ conference. Crit Care Med. 2012;40: 502–509.
  • 38. PICS in COVID-19 Patients • PICS: patients have an elevated rate of re-admission – Those with ALI/ARDS have higher rate of readmission (80%) – Longer index admission associated with higher healthcare cost after index admission – Degree of inflammation associated with development of PICS – Significant impact on home finances and ability to re-enter the workplace • In COVID: – Oxygen Demand: has the capacity to decrease • 6MW test and PFTs help with objectivity – Physical Therapy Remains extremely important – Totality of PICS in COVID-19 patients is not yet fully appreciated -Ruhl AP, Lord RK, Panek JA, Colantuoni E, Sepulveda KA, Chong A, et al. Health care resource use and costs of two-year survivors of acute lung injury: An observational cohort study. Ann Am Thorac Soc. 2015;12: 392–401. -Bangash MN, Owen A, Alderman JE, Chotalia M, Patel JM, Parekh D. COVID-19 recovery: potential treatments for post-intensive care syndrome. Lancet Respir Med. 2020;8: 1071–1073.
  • 39. Case #5 51 y.o. Male, no significant PMH, previously admitted for severe COVID-19 PNA at OSH- Ventilated – Trach – Decannulated • Course c/b failed extubation x 3, MRSA-VAP- Trach / PEG • Admitted 3/18/20 for COVID-19 PNA – Trach (4/23/20) – Decannulated (5/15/20) - Discharged (5/18/20) Home • 6/18- admitted at OSH for acute exacerbation of “Asthma” discharged on steroids and inhalers • 6/24- ED Visit at OSH for Dyspnea: duo-nebs – steroids, H1 blocker, inhalers- discharged • 6/26- ED Visit at OSH for Dyspnea: duo-nebs – steroids, discharged with 5 day steroid course • 6/28- admitted for Dyspnea, Hypoxia- stridor identified- underwent tracheal balloon dilation (7/1)- steroid taper, discharged with improved symptoms (7/2) with follow up scheduled
  • 40. Case #5: Initial Imaging
  • 41. Case #5: Spirometry and Imaging
  • 42. Case #5 Continued • 7/23: Re-admitted with progressive Dyspnea  Noted to have voice change • 7/25: Repeat balloon dilation with temporary improvement  Quickly relapsed with O2 demand (5L NC constantly)  No obvious stridor on exam  PFTs post dilation
  • 43. Case #5 Follow Up • 8/3: Patient underwent tracheal ring resection  Trach placed during procedure  Quickly decannulated (before discharge) • 8/10: Discharged home • Follow up with Speech for rehab therapy  Continues to have improvement. Mild raspy voice, otherwise asymptomatic  No requirement for supplemental oxygen
  • 44. Post-COVID “Long Hauler” Take-Home Messages • Oxygen supplementation: titration (as much physiologically as psychologically) – 6MW test / PFTs should be done at baseline and to monitor disease evolution • Inhalers: individual patient decision (LABA/ICS) • Anti-fibrotics: under investigation • Rehab therapy: extremely important- facilitation is key • PICS: weakness / cognition / depression / anxiety / PTSD / caretakers • Dyspnea: keep a broad differential in mind • Follow-up: elimination of barriers to healthcare access
  • 45. Barriers to Follow-Up Care • Disproportionate burden on racial / ethnic minority groups in hospitalization and death rates – Heavy Disease Burden on groups already vulnerable by traditional determinants of health indexes • Post-index hospitalization and Access to Care: – Language and Cultural Barriers • Navigation of the health system for testing / follow-up appointments • Insurance navigation – Economic Barriers: • Rehabilitation • DME – access to oxygen, prescriptions / refills • Home care : burden of care falls on family • Bread-winners: significant compromise in familial access to income
  • 46. COVID-19 for the “Long Haul” Questions Regarding Each Patient: 1. What ongoing issues are they facing? — Biological — Psychological — Social 2. Who is best-suited to address those issues? 3. What are the barriers the patient / family face in meeting their needs (from HCP perspective)? 4. How can we (individual providers / system) anticipate and help meet those demands?
  • 47. References • https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/late-sequelae accessed 12/28/20 • Carfì A, Bernabei R, Landi F, et al. Persistent symptoms in patients after acute COVID-19. JAMA. 2020;324(6):603-605. • del Rio C, Collins LF, Malani P. Long-term health consequences of COVID-19. JAMA. 2020. doi:10.1001/jama.2020.1971 • Fraser E. Long term respiratory complications of covid-19. BMJ. 2020;370:m3001. doi:10.1136/bmj.m3001 • Greenhalgh T, Knight M, A’Court C, et al. Management of post-acute covid-19 in primary care. BMJ. 2020;370:m3026 • Tenforde MW, Kim SS, Lindsell CJ, et al. Symptom duration and risk factors for delayed return to usual health among outpatients with COVID-19 in a multistate health care systems network— United States, March-June 2020. MMWR Morb Mortal Wkly Rep. 2020;69:993-998. • Sardari A, Tabarsi P, Borhany H, et al. Myocarditis detected after COVID-19 recovery, European Heart Journal – Cardiovascular Imaging. 2020. https://doi.org/10.1093/ehjci/jeaa166external icon • Lambert NJ and Survivor Corps. COVID-19 “Long Hauler” Symptoms Survey Report. Indiana University School of Medicine; 2020. https://dig.abclocal.go.com/wls/documents/2020/072720- wls-covid-symptom-study-doc.pdf • Halpin, SJ, McIvor, C, Whyatt, G, et al. Postdischarge symptoms and rehabilitation needs in survivors of COVID‐19 infection: A cross‐sectional evaluation. J Med Virol. 2020; 1– 10 • UK COVID Symptom study: https://covid.joinzoe.com/post/covid-long- term?fbclid=IwAR1RxIcmmdL-EFjh_aI- accessed 12/28/20
  • 48. Thank You! To learn more about The Path Forward series WeitzmanLearning.org/the-path-forward To view previous COVID-19 sessions: WeitzmanLearning.org/coronavirus